A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations is a phase 3, randomised interventional study registered as NCT07464327 by Hansoh BioMedical R&D Company, with a registry enrolment figure of 450 participants, started 2026-03-31 and due to reach its primary completion in 2028-12-31. Interventions recorded: HS-20093; Docetaxel. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR); Overall survival (OS). Lung eligibility wording from the registry: "Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)". No results are recorded here; the registry entry is the source.